血浆lncRNA SNHG12、miR-133b预测乳腺癌新辅助治疗效果的价值  

Value of plasma lncRNA SNHG12 and miR-133b in predicting the effect of neoadjuvant therapy for breast cancer

作　　者：高雪原 刘家麒[1] 陈洁清[1] 程学远[1] GAO Xueyuan;LIU Jiaqi;CHEN Jieqing;CHENG Xueyuan(Department of Gastrointestinal Surgery,Beihai People′s Hospital,Beihai,Guangxi 536000,China)

机构地区：[1]北海市人民医院胃肠外科,广西北海536000

出　　处：《检验医学与临床》2024年第20期2951-2957,共7页Laboratory Medicine and Clinic

基　　金：北海市科技计划项目(北科合202082044);北海市本级科学研究与技术开发项目(201602028)。

摘　　要：目的探讨血浆长非编码RNA小核仁宿主基因12(lncRNA SNHG12)、微小RNA(miR)-133b预测乳腺癌新辅助治疗效果的价值。方法选取2022年1月至2023年1月在该院进行新辅助治疗的86例乳腺癌患者作为乳腺癌组,依据新辅助治疗效果分为病理学完全缓解(pCR)组和non-pCR组。另选取同期在该院进行健康体检的50例健康女性作为对照组。检测并比较所有研究对象lncRNA SNHG12、miR-133b表达水平。采用多因素Logistic逐步回归模型分析影响乳腺癌新辅助治疗效果的因素。绘制受试者工作特征(ROC)曲线分析血浆lncRNA SNHG12、miR-133b单独及联合检测对乳腺癌新辅助治疗效果的预测价值。结果乳腺组血浆lncRNA SNHG12表达水平高于对照组,miR-133b表达水平低于对照组,差异均有统计学意义(P<0.05)。pCR组纳入34例患者,non-pCR组纳入52例患者。pCR组与non-pCR组雌激素受体、孕激素受体、人表皮生长因子受体-2(HER-2)、细胞增殖核抗原、分子分型比较,差异均有统计学意义(P<0.05)。pCR组lncRNA SNHG12表达水平低于non-pCR组,miR-133b表达水平高于non-pCR组,差异均有统计学意义(P<0.05)。多因素Logistic逐步回归分析结果显示,分子分型为HER-2过表达型、lncRNA SNHG12表达水平升高、miR-133b表达水平降低是乳腺癌新辅助治疗效果的危险因素(P<0.05)。ROC曲线分析结果显示,血浆lncRNA SNHG12、miR-133b单独检测预测乳腺癌患者新辅助治疗效果的曲线下面积(AUC)分别为0.850、0.951,均低于二者联合检测的0.963。86例乳腺癌中Luminal A型11例(pCR 1例、non-pCR 10例)、Luminal B型43例(pCR 12例、non-pCR 31例)、HER-2过表达型16例(pCR 14例、non-pCR 2例)、三阴型16例(pCR 7例、non-pCR 9例)。ROC曲线分析lncRNA SNHG12、miR-133b对4种不同亚型乳腺癌新辅助治疗效果的预测效能结果显示,血浆lncRNA SNHG12、miR-133b单独及联合检测预测Luminal B型乳腺癌患者新辅助治疗效果的AUC分别为0.Objective To investigate the value of plasma long non-coding RNA small nucleolar host gene 12(lncRNA SNHG12)and microRNA(miR)-133b in predicting the effect of neoadjuvant therapy for breast cancer.Methods A total of 86 patients with breast cancer who underwent neoadjuvant therapy in the hospital from January 2022 to January 2023 were selected as the breast cancer group,and were divided into pathological complete response(pCR)group and non-pCR group according to the effect of neoadjuvant therapy.Another 50 healthy women who underwent physical examination in the hospital during the same period were selected as the control group.The expression levels of lncRNA SNHG12 and miR-133b in all subjects were detected and compared.Multivariate Logistic stepwise regression model was used to analyze the factors affecting the effect of neoadjuvant therapy for breast cancer.The receiver operating characteristic(ROC)curve was drawn to analyze the predictive value of plasma lncRNA SNHG12 and miR-133b alone or in combination for the effect of neoadjuvant therapy in breast cancer.Results The expression level of plasma lncRNA SNHG12 in the breast group was higher than that in the control group,and the expression level of miR-133b was lower than that in the control group,and the differences were statistically significant(P<0.05).Thirty-four patients were included in the pCR group and 52 patients were included in the non-pCR group.There were significant differences in estrogen receptor,progesterone receptor,human epidermal growth factor receptor-2(HER-2),nuclear antigen of cell proliferation and molecular typing between the pCR group and the non-pCR group(P<0.05).The expression level of lncRNA SNHG12 in pCR group was lower than that in non-pCR group,and the expression level of miR-133b was higher than that in non-pCR group,and the differences were statistically significant(P<0.05).Multivariate Logistic stepwise regression analysis showed that HER-2 overexpression,increased expression level of lncRNA SNHG12 and decreased expression leve

关 键 词：长非编码RNA小核仁宿主基因12 微小RNA-133b 乳腺癌 新辅助治疗 病理学完全缓解 

分 类 号：R446.6[医药卫生—诊断学] R737.9[医药卫生—临床医学]